11 recruiting, 7 completed, 4 withdrawn, 3 active not recruiting. 18 Phase 2, 6 Phase 1, 4 Not applicable, 1 Phase 4.
Follow Angiosarcoma: new trials by email Literature Review of Angiosarcoma trials Research Report on Angiosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma Vusolimogene Oderparepvec (VO), Pembrolizumab - Angiosarcoma, Angiosarcoma, Adult | Phase 2 | Recruiting | Varun Monga, MBBS | 18 | 2026-01-09 | 2026-09-01 |
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-02-25 | 2026-01-08 |
| Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma Biopsy, Chest Computed Tomography, Chest Radiography - Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma | Not applicable | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 1582 | 2025-01-28 | 2024-07-30 |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors AGX101 - Cancer, Advanced Cancer | Phase 1 | Recruiting | Angiex, Inc. | 80 | 2024-07-22 | 2026-09-09 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars Observational - Angiosarcoma | Recruiting | Italian Sarcoma Group | 250 | 2024-03-29 | 2025-11-20 | |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma Paclitaxel, mRNA plus Lysate-loaded Dendritic Cell Vaccine, PEGYLATED-INTERFERON ALPHA-2A - Angiosarcoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2024-03-22 | 2026-02-13 | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-05-04 | 2026-08-12 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients Observational Translational Study - Sarcoma, Sarcoma, Leiomyo-, Adult | Recruiting | Royal Marsden NHS Foundation Trust | 800 | 2021-11-19 | 2026-02-25 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Propranolol, Pembrolizumab - Soft Tissue Sarcoma Adult, Angiosarcoma | Phase 2 | Recruiting | Niels Junker | 80 | 2021-08-17 | 2023-07-27 |
| AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma AGEN2034, AGEN1884 - Angiosarcoma | Phase 2 | Withdrawn | Agenus Inc. | 2021-02-01 | 2022-01-11 | |
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas Treatment by Regorafenib, Surveillance - Bone Sarcoma, Osteosarcoma | Not applicable | Recruiting | Centre Leon Berard | 168 | 2020-03-03 | 2026-02-17 |
| Propranolol in Angiosarcoma Propranolol - Angiosarcoma | Phase 2 | Completed | The Netherlands Cancer Institute | 14 | 2019-12-27 | 2023-11-22 |
| Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma CICS-1 (investigational device),SPM-011(investigational drug) - Malignant Melanoma, Angiosarcoma | Not applicable | Completed | Cancer Intelligence Care Systems, Inc. | 10 | 2019-11-19 | 2023-02-08 |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer Botensilimab, Balstilimab - Advanced Cancer, Angiosarcoma | Phase 1 | Active not recruiting | Agenus Inc. | 499 | 2019-03-20 | 2026-03-30 |
| Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) Eribulin - Angiosarcoma, Epithelioid Hemangioendothelioma | Phase 2 | Completed | Massachusetts General Hospital | 13 | 2018-01-18 | 2026-08-28 |
Showing 20 of 29. Sign in to see all of them.
Hemangiosarcoma (29) · Leiomyosarcoma (11) · Sarcoma (11) · Liposarcoma (8) · Histiocytoma, Malignant Fibrous (7) · Neurofibrosarcoma (7) · Fibrosarcoma (6) · Sarcoma, Synovial (6) · Dermatofibrosarcoma (5) · Osteosarcoma (4) · Bone Neoplasms (3) · Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Adenoid Cystic (2) · Carcinoma, Basal Cell (2)
Neoplasms by Histologic Type (29) · Neoplasms, Connective and Soft Tissue (29) · Neoplasms, Vascular Tissue (29) · Neoplasms (26) · Sarcoma (18) · Neoplasms, Connective Tissue (12) · Neoplasms, Fibrous Tissue (12) · Neoplasms, Muscle Tissue (11) · Neoplasms by Site (10) · Neoplasms, Nerve Tissue (9) · Histiocytoma (7) · Neoplasms, Adipose Tissue (7) · Nervous System Diseases (7) · Nervous System Neoplasms (7) · Neurofibroma (7)
Doxorubicin (4) · Paclitaxel (4) · pembrolizumab (4) · Docetaxel (3) · Gemcitabine (3) · Ipilimumab (3) · Propranolol (3) · spartalizumab (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Bevacizumab (2) · Ifosfamide (2) · Nivolumab (2) · Standard of Care (2) · balstilimab (2) · pazopanib (2)
Agenus Inc. (2) · Brown University (2) · Centre Oscar Lambret (2) · Memorial Sloan Kettering Cancer Center (2) · Angiex, Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · Cancer Intelligence Care Systems, Inc. (1) · Centre Leon Berard (1) · ECOG-ACRIN Cancer Research Group (1) · Fudan University (1) · Guerbet (1) · HRYZ Biotech Co. (1) · Heidelberg University (1) · Instituto do Cancer do Estado de São Paulo (1) · Italian Sarcoma Group (1)
United States (12) · France (4) · China (2) · United Kingdom (2) · Austria (1) · Brazil (1) · Denmark (1) · Germany (1) · Guam (1) · India (1) · Italy (1) · Japan (1) · Netherlands (1) · Norway (1) · Sweden (1)
Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Brian A Van Tine, M.D., Ph.D. (1) · Camila MV Moniz, Doctor (1) · Don S Dizon, MD (1) · Elena Palassini (1) · Galina G Lagos, MD (1) · Glen Weiss, MD (1) · Gregory Cote, MD, PhD (1) · Jessica Gartrell, MD (1) · Jing Hao, MD (1) · Kenneth Cardona (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 30305054, PMID 31969335, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34529000, PMID 34716198, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38243705, PMID 38358334, PMID 38745646, PMID 38871975, PMID 38986056, PMID 39067873, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39613746, PMID 39625569, PMID 39856213, PMID 39869830, PMID 40402690, PMID 40526879, PMID 40551254, PMID 40588371, PMID 40639409, PMID 40679371
2009 (1), 2015 (1), U10CA180888 (1), UG1CA189828 (1)